Researchers in the second pivotal study evaluating the safety and efficacy of avacincaptad pegol (Zimura, IVERIC bio) for the treatment of geographic atrophy have released 1-year results. New Retina Radio spoke with Arshad Khanani, MD, MS, about the GATHER2 study findings. How did the study results compare to the GATHER1 conclusions—and might the company move forward with a regulatory filing?
Fler avsnitt av New Retina Radio by Eyetube
Visa alla avsnitt av New Retina Radio by EyetubeNew Retina Radio by Eyetube med Retina Today finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.